Stefan Löb1, Alfred Königsrainer. 1. Department of General, Visceral and Transplantsurgery, Eberhard Karls University, Tübingen, Germany. stefan.loeb@med.uni-tuebingen.de
Abstract
BACKGROUND: Shaping immune responses to prevent tumor-induced tolerance or transplant rejection after solid organ transplantation is a permanently expanding field of research. Immunological tolerance, in this case, is a double-edged sword. Tumors escape immune surveillance by creating an abnormal state of tolerance towards their own antigens, whereas transplantation medicine is challenged to develop new strategies to induce allograft-specific immunological tolerance. One mechanism possibly capable of achieving immunoregulation is based on indoleamine-2,3-dioxygenase (IDO). OBJECTIVE: This overview article focuses on IDO-mediated tryptophan catabolism with special regard to its role in cancer and transplantation immunology. RESULTS: The historical view about IDO as a host's antimicrobial defence mechanism has been extended by the observation that its expression is essential for successful allogeneic pregnancy. Subsequent studies analysing IDO as an immune-regulatory enzyme describe its implications in cancer immune escape, as chemical abrogation of enzyme activity with 1-methyl-tryptophan (1-MT), results in enhanced antitumor responses in animal models. Therefore, a clinical trial treating cancer patients with 1-MT has been started. IDO also seems to play an essential role in the control of allo- and autoreactive T cell responses. CTLA4-Ig is able to induce IDO expression in dendritic cells (DCs) and consequently renders them tolerogenic, which might provide one explanation for the observed therapeutic effects of abatacept and belatacept. CONCLUSION: There is evidence that IDO achieves immune modulation in several animal models. However, in humans, this remains controversially discussed.
BACKGROUND: Shaping immune responses to prevent tumor-induced tolerance or transplant rejection after solid organ transplantation is a permanently expanding field of research. Immunological tolerance, in this case, is a double-edged sword. Tumors escape immune surveillance by creating an abnormal state of tolerance towards their own antigens, whereas transplantation medicine is challenged to develop new strategies to induce allograft-specific immunological tolerance. One mechanism possibly capable of achieving immunoregulation is based on indoleamine-2,3-dioxygenase (IDO). OBJECTIVE: This overview article focuses on IDO-mediated tryptophan catabolism with special regard to its role in cancer and transplantation immunology. RESULTS: The historical view about IDO as a host's antimicrobial defence mechanism has been extended by the observation that its expression is essential for successful allogeneic pregnancy. Subsequent studies analysing IDO as an immune-regulatory enzyme describe its implications in cancer immune escape, as chemical abrogation of enzyme activity with 1-methyl-tryptophan (1-MT), results in enhanced antitumor responses in animal models. Therefore, a clinical trial treating cancerpatients with 1-MT has been started. IDO also seems to play an essential role in the control of allo- and autoreactive T cell responses. CTLA4-Ig is able to induce IDO expression in dendritic cells (DCs) and consequently renders them tolerogenic, which might provide one explanation for the observed therapeutic effects of abatacept and belatacept. CONCLUSION: There is evidence that IDO achieves immune modulation in several animal models. However, in humans, this remains controversially discussed.
Authors: David H Munn; Madhav D Sharma; Jeffrey R Lee; Kanchan G Jhaver; Theodore S Johnson; Derin B Keskin; Brendan Marshall; Phillip Chandler; Scott J Antonia; Russell Burgess; Craig L Slingluff; Andrew L Mellor Journal: Science Date: 2002-09-13 Impact factor: 47.728
Authors: Weifang Ling; Jimin Zhang; Zengrong Yuan; Guangwen Ren; Liying Zhang; Xiaodong Chen; Arnold B Rabson; Arthur I Roberts; Ying Wang; Yufang Shi Journal: Cancer Res Date: 2014-01-22 Impact factor: 12.701
Authors: Jason C O'Connor; Marcus A Lawson; Caroline André; Eileen M Briley; Sandra S Szegedi; Jacques Lestage; Nathalie Castanon; Miles Herkenham; Robert Dantzer; Keith W Kelley Journal: J Immunol Date: 2009-03-01 Impact factor: 5.422
Authors: Carlos E A Batista; Csaba Juhász; Otto Muzik; William J Kupsky; Geoffrey Barger; Harry T Chugani; Sandeep Mittal; Sandeep Sood; Pulak K Chakraborty; Diane C Chugani Journal: Mol Imaging Biol Date: 2009-05-12 Impact factor: 3.488
Authors: Brett C DiNatale; Iain A Murray; Jennifer C Schroeder; Colin A Flaveny; Tejas S Lahoti; Elizabeth M Laurenzana; Curtis J Omiecinski; Gary H Perdew Journal: Toxicol Sci Date: 2010-01-27 Impact factor: 4.849